Literature DB >> 29399863

Photodynamic therapy in patients with head and neck squamous cell carcinoma.

Seiji Hosokawa1, Satoru Takebayashi1, Goro Takahashi1, Jun Okamura1, Hiroyuki Mineta1.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is a minimally invasive treatment for malignant tumors. The aim of this study was to determine the efficacy of PDT in patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: Thirty-three patients with HNSCC were treated with porfimer sodium-mediated PDT followed by intraoperative light activation at 630 nm via fiber optic microlens delivered after 48 hours of injection.
RESULTS: The complete response (CR) rate was 72.7%, while the efficacy (CR + partial response) rate was 97.0%. The rate of good local control (i.e., CR without recurrence after PDT) achieved after the initial PDT (82.6%) was significantly higher than that achieved after the second or third PDT (10%); this rate remained at 62.1% without functional disturbance and disfigurement even after excluding four previously untreated patients. The final local control rate following PDT plus additional therapies was 73.8%.
CONCLUSIONS: PDT is an effective therapy to treat HNSCC, and leads to an improved quality of life in patients with residual or recurrent disease. Lasers Surg. Med. 50:420-426, 2018.
© 2018 Wiley Periodicals, Inc. © 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  head and neck squamous cell carcinoma; photodynamic therapy; porfimer sodium; recurrent cancer; residual cancer

Mesh:

Substances:

Year:  2018        PMID: 29399863     DOI: 10.1002/lsm.22802

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  1 in total

1.  Tumor cytotoxicity and immunogenicity of a novel V-jet neon plasma source compared to the kINPen.

Authors:  Lea Miebach; Eric Freund; Stefan Horn; Felix Niessner; Sanjeev Kumar Sagwal; Thomas von Woedtke; Steffen Emmert; Klaus-Dieter Weltmann; Ramona Clemen; Anke Schmidt; Torsten Gerling; Sander Bekeschus
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.